177Lu-PSMA-I&T for Metastatic Castration-Resistant Prostate Cancer

Authors
Category Primary study
Registry of TrialsClinicalTrials.gov
Year 2022
A Multi-Center, Open-Label, Randomized Phase 3 Trial Comparing the Safety and Efficacy of 177Lu-PSMA-I\&T versus Hormone Therapy in Patients with Metastatic Castration-Resistant Prostate Cancer.
Epistemonikos ID: 9a4a0cbec81aad58f0ee6444e1555c31370be178
First added on: Oct 02, 2023